Authors: Marek Broul 1-3; Aneta Hujová 3; Kateřina Langmaierová 4; Michaela Liegertová 5 Authors‘ workplace: Sexuologické oddělení, Krajská zdravotní, a. s. – Masarykova nemocnice v Ústí nad Labem, o. z. 1; Urologické oddělení, Krajská zdravotní, a. s. – Nemocnice Litoměřice, o. z. 2; Fakulta zdravotnických studií UJEP v Ústí nad Labem 3; Oddělení klinické farmacie, Krajská zdravotní, a. s. – Masarykova nemocnice v Ústí nad Labem, o. z. 4; Přírodovědecká fakulta UJEP v Ústí nad Labem 5 Published in: Čas. Lék. čes. 2026; 165: 3-6 Category: Review Article
Drug-induced sexual dysfunction (iatrogenic sexual dysfunction) ranks among the most common, least reported, and at the same time clinically most significant adverse effects of long-term pharmacotherapy in men. In clinical practice, it typically manifests as reduced libido, erectile dysfunction (ED), ejaculatory disorders, orgasmic dysfunction, or a combination of several phenotypes, while the temporal relationship to treatment initiation or dose titration may be subtle.
The aim of this article is to provide a pragmatic, implementable algorithm for the outpatient physician, integrating sexuological assessment with a basic pharmacological analysis (likelihood of a drug-related cause, dose dependence, interactions, substitution options) and recommended interventions, including the safe use of phosphodiesterase type 5 (PDE5) inhibitors in ED.
antidepressants – Antipsychotics – Erectile dysfunction – adverse drug reactions – drug-induced sexual dysfunction – ejaculatory disorders
1. Salonia A, Capogrosso P, Boeri L et al. European Association of Urology Guidelines on male sexual and reproductive Health: 2025 update on male hypogonadism, erectile dysfunction, premature ejaculation, and Peyronie’s disease. Eur Urol 2025; 88 : 76–102.
2. Gravas S, Gacci M, Gratzke C et al. Summary paper on the 2023 European Association of Urology guidelines on the management of non‑neurogenic male LUTS. Eur Urol 2023; 84 : 207–222.
3. Taylor MJ, Rudkin L, Bullemor-Day P. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev 2022; 4: CD003382.
4. PRAC recommendations on signals adopted at the 13-16 May 2019 PRAC meeting: SSRI/SNRI – persistent sexual dysfunction after drug withdrawal. EMA/PRAC/265212/2019. European Medicines Agency, 2019. Dostupné na: www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-13-16-may-2019-prac-meeting_en.pdf
5. Finasterid a dutasterid: upozornění na riziko sebevražedných myšlenek a změn nálady; nežádoucí účinky mohou zahrnovat poruchy sexuálních funkcí. Státní ústav pro kontrolu léčiv, 9. 5. 2025. Dostupné na: https://sukl.gov.cz/farmakovigilance-cs/dulezite-informace-a-upozorneni-k-bezpecnosti-leciv/finasterid-dutasterid-ukonceno-celoevropske-prehodnoceni-rizika-sebevrazednych-myslenek-a-sebevrazedneho-chovani
6. Rosen RC, Riley A, Wagner G. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49 : 822–830.
7. O’Rourke TK Jr, Wosnitzer MS. Opioid‑induced androgen deficiency (OPIAD): diagnosis, management, and literature review. Curr Urol Rep 2016; 17 : 76.
8. Jiang Q, Li T, Zhao L et al. Treatment of antipsychotic-induced hyperprolactinemia: an umbrella review of systematic reviews and meta-analyses. Front Psychiatry 2024; 15 : 1337274.
9. Montejo AL, de Alarcón R, Prieto N et al. Management strategies for antipsychotic-related sexual dysfunction: a clinical approach. J Clin Med 2021; 10 : 308.
10. Lou IX, Chen J, Ali K, Chen Q. Relationship between hypertension, antihypertensive drugs and sexual dysfunction in men and women: a literature review. Vasc Health Risk Manag 2023; 19 : 691–705.
11. Fertig RM, Gamret AC, Darwin E, Gaudi S. Sexual side effects of 5-alpha-reductase inhibitors finasteride and dutasteride: a comprehensive review. Dermatol Online J 2017; 23 : 13030/qt24k8q743.
12. Broul M. Kazuistiky v sexuologii. EEZY Publishing, Praha, 2025.
13. Broul M, Hujová A, Radovnická L et al. Hyperprolactinemia-associated erectile dysfunction: retrospective cohort evaluating the effect of prolactin normalization on IIEF-5. Neuro Endocrinol Lett 2025; 46 : 107–114.
14. Rosen RC, Cappelleri JC, Smith MD et al. Development and evaluation of an abridged, 5‑item version of the International Index of Erectile Function (IIEF‑5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11 : 319–326.
15. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 : 239–245.
16. Zhao B, Hong Z, Wei Y, et al. Erectile dysfunction predicts cardiovascular events as an independent risk factor: a systematic review and meta-analysis. J Sex Med 2019 : 1005–1017.
17. Köhler TS, Kloner RA, Rosen RC et al. The Princeton IV Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2024; 99 : 1500–1517.
18. Healy D, Mangin D. Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence. Epidemiol Psychiatr Sci 2024; 33: e40
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
